Clinical Trials Logo

Medullary Thyroid Cancer clinical trials

View clinical trials related to Medullary Thyroid Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06243965 Completed - Clinical trials for Medullary Thyroid Cancer

Is Desmoplastic Stromal Reaction Useful to Modulate Lymph Node Dissection in Sporadic Medullary Thyroid Carcinoma?

DSR-MTC
Start date: January 1, 1997
Phase:
Study type: Observational

The oncologic benefit of lateral neck dissection (LND) during index operation for sporadic medullary thyroid carcinoma (MTC) basing on basal calcitonin (bCT) levels has been questioned due to the potential post-operative complications. This study aims to evaluate desmoplastic reaction (DSR), as predictor of nodal metastases, for definition of surgical strategy. Data from pathological report of MTC after operations between 1997 and 2022 were collected. The primary endpoint of the study was evaluating the risk factors for nodal metastases. The secondary endpoints analyzed the correlations between DSR and nodal metastases and the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of DSR for nodal metastases.

NCT ID: NCT03037385 Completed - Neoplasms Clinical Trials

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

ARROW
Start date: March 17, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.

NCT ID: NCT02856347 Completed - Clinical trials for Medullary Thyroid Cancer

Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin

CMTpostopFDOPA
Start date: March 22, 2017
Phase: N/A
Study type: Interventional

The aim of the trial is to study a radiating diagnosis agent used in post surgery when the biological assessment highlighted a residual disease. This is an inter-regional multicentric, prospective study evaluating the benefit of PET F-DOPA imaging in involved node detection compared to standard imaging assessment in patient with medullary thyroid cancer. The purpose of the study is to evaluate the impact and performance of a new PET / CT (computerized tomography ) tracer targeting dopamine receptor in patient with residual ganglionar biological disease after initial surgery of medullary thyroid cancer compared to standard imaging. Obtained data will be compared to the "gold standard" based on : - nodes cytology when they could be punctured - histology when a new surgery will be recommended - surveillance when the 2 first cases will be not applicable (imaging monitoring, evolution of thyrocalcitonin)

NCT ID: NCT02465424 Completed - Clinical trials for Medullary Thyroid Cancer

Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients

QaLM
Start date: December 2015
Phase:
Study type: Observational

The purpose of this study is to determine which Health Related Quality of Life (HRQoL) tools patients with medullary thyroid cancer (MTC) find most helpful. The study will compare a generic cancer QoL tool with those developed for thyroid cancer patients and neuroendocrine tumour (NET) patients. The study will also evaluate clinicians' opinions on the clinical usefulness of the QoL tools.

NCT ID: NCT01757470 Completed - Clinical trials for Medullary Thyroid Cancer

Vandetanib Risk Minimisation Effectiveness

Start date: June 2012
Phase: N/A
Study type: Observational

Effectiveness of risk minimisation interventions for vandetanib in Canada

NCT ID: NCT01625520 Completed - Clinical trials for Medullary Thyroid Cancer

SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer

Start date: February 2012
Phase: Phase 2
Study type: Interventional

A mono centre study to evaluate the efficacy of SOM230 in patients with progressive metastatic or postoperative persistent medullary thyroid cancer.

NCT ID: NCT01539655 Completed - Clinical trials for Medullary Thyroid Cancer

Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib

Vandetanib
Start date: February 2012
Phase: Phase 1
Study type: Interventional

Study in healthy volunteers to assess effect of omeprazole and ranitidine on the pharmacokinetics of vandetanib